ALLO

Allogene Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 5/10
  • Momentum↑ 8/10
Allogene Therapeutics sales and earnings growth
ALLO Growth
Neutral
  • Revenue Y/Y↓ -100.00%
  • EPS Y/Y↑ 37.18%
  • FCF Y/Y↑ 27.05%
Allogene Therapeutics gross and profit margin trends
ALLO Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -53.00%
Allogene Therapeutics net debt vs free cash flow
ALLO Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -250.0

Allogene Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗